Bolm Louisa, Käsmann Lukas, Paysen Annika, Karapetis Chris, Rades Dirk, Wellner Ulrich F, Keck Tobias, Watson David I, Hummel Richard, Hussey Damian J
Department of Surgery, UKSH Campus Luebeck, University of Luebeck, Luebeck, Germany.
Department of Radiation Oncology, UKSH Campus Luebeck, University of Luebeck, Luebeck, Germany.
Anticancer Res. 2018 Jun;38(6):3231-3242. doi: 10.21873/anticanres.12588.
Upper gastrointestinal malignancies are associated with a high disease burden worldwide, and esophageal and gastric cancers represent the most common entities. Given a lack of early characteristic symptoms and potent screening instruments, the majority of patients present with advanced disease at the time of diagnosis. Complete surgical resection is a first-line curative option, and multimodal approaches involving chemotherapy and radiotherapy further improve patient prognosis. However, response to standard adjuvant and neoadjuvant treatments remains low, and new strategies are warranted to increase tumor control rates. Immunotherapy is emerging in various cancer entities and may be successfully combined with standard therapeutic regimens to improve patient outcome. For the purpose of this review we aimed to assess combined approaches of immunotherapy and standard treatment options such as chemotherapy, radiotherapy and surgery. Current trials evaluating multimodal approaches with immunotherapy in esophageal and gastric cancer are evaluated.
上消化道恶性肿瘤在全球范围内具有很高的疾病负担，食管癌和胃癌是最常见的类型。由于缺乏早期特征性症状和有效的筛查手段，大多数患者在诊断时已处于疾病晚期。完整的手术切除是一线治愈性选择，包括化疗和放疗的多模式方法可进一步改善患者预后。然而，对标准辅助治疗和新辅助治疗的反应仍然较低，因此需要新的策略来提高肿瘤控制率。免疫疗法正在各种癌症类型中兴起，并且可以成功地与标准治疗方案联合使用以改善患者预后。出于本综述的目的，我们旨在评估免疫疗法与化疗、放疗和手术等标准治疗选择的联合方法。对目前评估食管癌和胃癌免疫疗法多模式方法的试验进行了评估。
